I got one for you (just came up with it). As pseudoprogression became a major issue the company made a strategic decision to move towards OS but were confronted with the crossover issue. So they decided to ditch placebo altogether with the goal of increasing the treatment arm to be compared with external placebos.
The point is, there are too many unknowns and we are just speculating.
News 
Market Data 
Discover 
AI
